An ergot derivative in the treatment of Parkinson's disease
Calne, D.B.; Shoulson, I.; Kartzinel, R.
Postgraduate Medical Journal 52suppl 1: 81-85
1976
ISSN/ISBN: 0032-5473 PMID: 183198 Document Number: 105056
Document emailed within 1 workday
Related Documents
Rasmussen, V.G.; Poulsen, S.H.; Dupont, E.; Østergaard, K.; Safikhany, G.; Egeblad, H. 2009: Heart abnormalities in Parkinson patients after discontinuation or continuation of ergot-derived dopamine agonists: a treatment-blinded echocardiographic study Journal of Heart Valve Disease 18(4): 463-469Robbers, J.E.; Jones, L.G.; Krupinski, V.M. 1974: Ergot physiology. the production of ergot alkaloids in saprophytic culture by a homokaryotic strain of ergot Lloydia 37(1): 108-111
Hoffman, W.; Rostock, A.; Siegemund, C.; Bartsch, R. 1989: AWD 52-39, an ergot derivative with potential nootropic activity Activitas Nervosa Superior 31(1): 56-57
Rack, M.J.; Baran, A.Sinan.; Richert, A.C.; Roffwarg, H.P. 2004: Cardiopulmonary complications of ergot-derivative dopamine agonists Journal of Clinical Psychiatry 65(10): 1429-30; Author Reply 1430
Vickers, A.E.; Connors, S.; Zollinger, M.; Biggi, W.A.; Larrauri, A.; Vogelaar, J.P.; Brendel, K. 1993: The biotransformation of the ergot derivative CQA 206-291 in human, dog, and rat liver slice cultures and prediction of in vivo plasma clearance Drug Metabolism and Disposition: the Biological Fate of Chemicals 21(3): 454-459
Cahn, J.; Borzeix, M.G. 1983: Cerebral blood flow and metabolism, and neurologic deficit in an experimental infarction. Application to the study of an ergot derivative Presse Medicale 12(48): 3058-3060
Jiménez Jiménez, F.J.; Ladero Quesada, J.M. 1990: An experimental model of Parkinson disease caused by a neurotoxin: implications in the clinical aspects and the etiology of Parkinson disease Medicina Clinica 94(15): 585-595
Tanasanvimon, S.; Ayuthaya, N.I.N.; Phanthumchinda, K. 2007: Modified Parkinson's Disease Sleep Scale (MPDSS) in Thai Parkinson's disease patients Journal of the Medical Association of Thailand 90(11): 2277-2283
Hattori, N. 2004: Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease Rinsho Shinkeigaku 44(4-5): 241-262
Jankovic, J. 2001: Parkinson's disease therapy: treatment of early and late disease Chinese Medical Journal 114(3): 227-234
Sale, P.; De Pandis, M.F.; Vimercati, S.L.; Sova, I.; Foti, C.; Tenore, N.; Fini, M.; Stocchi, F.; Albertini, G.; Franceschini, M.; Galli, M. 2013: The relation between Parkinson's disease and ageing. Comparison of the gait patterns of young Parkinson's disease subjects with healthy elderly subjects European Journal of Physical and Rehabilitation Medicine 49(2): 161-167
Rasmussen, V.G.; Dupont, E.; Østergaard, K.; Egeblad, H. 2006: Valvular heart disease associated with the treatment of Parkinson disease Ugeskrift for Laeger 168(26-32): 2542-2544
Rabasseda, X. 1999: Perspectives in the treatment of Parkinson's disease: COMT inhibitors open up new treatment strategies Drugs of Today 35(9): 701-717
Jameson, H.D. 1972: Treatment of Parkinson's disease Journal of the Kentucky Medical Association 70(4): 304-307
Jiménez-Jiménez, F.J. 1999: The treatment of Parkinson disease Medicina Clinica 112(7): 257-258
Bergus, G. 1996: Treatment of Parkinson's disease Journal of Family Practice 42(5): 457-458
Vijayaraghavan, A.; Radhakrishnan, K. 1996: Treatment of Parkinson's disease Neurology India 44(4): 177-182
Vijayaraghavan, A.; Radhakrishnan, K. 1995: Treatment of Parkinson's disease Neurology India 43(2): 77-82
Grieger, T.A.; Cozza, K.; Armstrong, S. 1994: Treatment of Parkinson's disease New England Journal of Medicine 330(9): 643-644
Fénelon, G. 1997: Diagnosis and course (under treatment) of Parkinson disease La Revue du Praticien 47(10): 1062-1067